Company provides advanced IoT Platform and wearable sensors to capture health vital signs for clinical trials and patient care.
- Investment between Niterra Co., Ltd. CVC Fund and Pegasus Tech Ventures supports technology detecting and assessing Cardiology, Oncology, Neurology, and Hypertension conditions
- Vivalink Medical, Inc. (CA, USA) technology has been installed in 45 countries worldwide, granted 20 patents, and utilized in 21 research institutions. The company is collaborating with 250+ commercial partners
- Investment enhances healthcare with clinical grade physiology metrics powered by wearable sensors, network data services, algorithms, and clinician portals
Niterra (formerly NGK Spark Plug Co. LTD, Headquarters: Higashi-Ku, Nagoya) provided a strategic joint-partnership investment through the CVC fund jointly operated with Pegasus Tech Ventures (Headquarters: CA, USA) to a remote patient monitoring services company, Vivalink Medical, Inc (Headquarters: CA, USA), that specializes in home healthcare, telemedicine, and wearable technology.
Niterra is in charge of creating new revenue streams to realize the “2030 Long-Term Management Plan NITTOKU BX,” which outlines the transformation of the business portfolio towards an increase of the ratio of businesses not related to the internal combustion engine. To achieve this, Niterra plans to promote the creation of new businesses in the areas of Healthcare, Energy and Environment, Mobility, and Communications. As part of Niterra’s efforts in Healthcare, the company is developing and investing in innovative home health and point-of-care solutions as their long-term growth strategy.
“Our vision at Niterra is to improve the quality of life for everybody,” said Dirk Schapeler, President of Niterra Ventures Company. “We partner with the best industry professionals and brightest entrepreneurs to develop remote patient monitoring platforms to serve advanced patient care at home and medical environments.”
Vivalink is a provider of digital healthcare solutions including biometrics for virtual patient care and decentralized clinical trials. They leverage unique physiology-optimized medical wearable sensors and related data services to enable a deeper and more clinical understanding between provider and patient. In addition, they have a track record of business operations in 45 countries around the world, FDA/CE/NMPA clearance, and are compliant with the Personal Information Data Protection Directive and related regulations (HIPAA, GDPR).
Vivalink has delivered over a decade of health tech innovations and a broad array of successful milestones, which includes development of a first-of-its-kind when presented eSkin technology, launching a temperature monitor, launching a medical wearable sensor, FDA & CE Clearance of an ECG platform, and various clinical trials.
“We are proud to have Niterra and Pegasus Tech Ventures as a key strategic investment partner to the Vivalink Team,” said Jiang Li, Founder & Chief Executive Officer of Vivalink. “This investment allows Vivalink to accelerate the development of our platform and its commercial growth worldwide. Our shared vision is to help healthcare organizations and patients be successful with faster time to market, a regulatory cleared platform, lower development costs, and common infrastructure.”
Overview of Vivalink Remote Patient Monitoring (RPM)
Vivalink’s biometric platform accelerates the deployment of virtually any type of remote patient monitoring application for healthcare and clinical trials. Examples of these RPM applications include cardiac arrhythmia, cryptogenic stroke, cardiac rehab, COPD, neutropenia, and cytokine release syndrome.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
